Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Model system identifies new FHV-1 drug
Black cat eye
The team identified the drug while developing a model to test drugs that treat feline eye infections.

Raltegravir requires only once-a-day dosing

A model system developed to test medication for feline herpesvirus 1 (FHV-1) has identified a new drug that only needs to be applied once-a-day.

Identified by scientists at Cornell's College of Veterinary Medicine, raltegravir is used in humans to treat HIV infections, but it had never been used to treat FHV-1 in cats.

“We found that it is very effective against FHV-1. It even worked when we applied the drug only once every 24 hours,” says study leader Dr Gerlinde Van de Walle.

The team identified the drug while developing a model to test drugs that treat feline eye infections.

Described in the Journal of General Virology, the new model used corneas donated from cats that died of causes other than eye disease. Researchers say this method offers a better reflection of what happens in the eyes of a cat, than models consisting of cells in a petri dish.

In the study, the team applied the FHV-1 virus to some of the corneas and tested the effectiveness of two commonly prescribed drugs: cidofovir and acyclovir.

Both drugs cleared the infection when applied every 12 hours, but cidofovir was more effective.

The team then used the model system to test raltegravir. They found that it was just as effective as other drugs for treating FHV-1 infections and only needed to be administered once a day.

Dr Walle says that she eventually hopes to see the drug tested in a well-controlled clinical trial.

Become a member or log in to add this story to your CPD history

Building Great Workplaces webinars return

News Story 1
 BVA has announced a new series of its Building Great Workplaces lunchtime webinars.

Launching from 16 July, the sessions will explore patient safety, motivation, client communication and more.

Its first webinar, exploring neurodiversity in the workplace, will take place at 1pm on Thursday, 16 July. It will feature guest speakers from The Vet Project, a group which supports neurodiversity in veterinary environments.

The following three webinars take place in September, October and November.

Booking is open on the BVA website 

Click here for more...
News Shorts
New form for online veterinary medicines retailers

The Veterinary Medicines Directorate (VMD) has produced a new online form for retailers wishing to sell veterinary medicines on the internet.

The form replace the previous Word version and is part of the VMD's ongoing commitment to digitise its processes. Anyone retailing prescription medicines online, including POM-V, POM-VPS and NFA-VPS categories, is lawfully required to register with the VMD before trading.

The change only applies to new applicants. Retailers already listed on the VMD's Register of Online Retailers or registered under the Accredited Internet Retailer Scheme (AIRS) do not need to do anything.